TABLE 3.
Ongoing clinical trials involving Apatinib (VEGFR2 inhibitor) in HCC.
| Name | Trail ID | Phase | Study population | Intervention | Status |
| Apatinib | NCT03046979 | II | Advanced HCC patients | Apatinib | Unknown |
| Apatinib and TACE | NCT03066557 | Not Applicable | HCC patients | TACE and Apatinib | Unknown |
| Apatinib | NCT01192971 | II | Advanced HCC patients | Apatinib | Completed |
| Apatinib | NCT02727309 | I/II | Advanced HCC patients | Apatinib after TACE | Unknown |
| Apatinib and Camrelizumab | NCT04521153 | Not Applicable | Resectable HCC patients | Camrelizumab and Apatinib Mesylate Procedure: TACE treatment and radical surgery | Recruiting |
| SHR-1210 and Apatinib | NCT04297202 | II | HCC patients | Apatinib combined with SHR-1210 injection | Recruiting |
| Apatinib and Capecitabine | NCT03114085 | II | Advanced HCC patients | Capecitabine and Apatinib compared with Apatinib | Unknown |
| Cryoablation, Camrelizumab and Apatinib | NCT04724226 | II | Advanced HCC patients | Cryoablation, Camrelizumab, Apatinib | Not yet recruiting |
| SHR-1210 Plus Apatinib | NCT04014101 | II | Advanced stage HCC | SHR-1210 and Apatinib | Recruiting |
| Apatinib | NCT02772029 | I/II | Advanced HCC Patients After First-line Treatment Failure | Apatinib Mesylate Tablets | Unknown |
| SHR-1210 Plus Apatinib | NCT03722875 | Not Applicable | BCLC B and C stage HCC after surgery | SHR-1210 and Apatinib | Unknown |
| Sintilimab, Apatinib and Capecitabine | NCT04411706 | II | Advanced HCC patients | Sintilimab Combined With Apatinib and Capecitabine | Recruiting |
| Apatinib | NCT03511703 | II | Advanced HCC | Postoperative adjuvant Apatinib vs. TACE, chemotherapy drugs + iodized | Unknown |
| Apatinib and Camrelizumab | NCT04191889 | II | C-staged HCC patients | Hepatic Arterial Infusion with Apatinib and Camrelizumab | Recruiting |
| Apatinib plus radiotherapy | NCT03520257 | II | HCC patients with BCLC-C stage I and II portal vein tumor thrombus | Apatinib plus radiotherapy vs. Apatinib | Unknown |
| Camrelizumab, Apatinib and Oxaliplatin | NCT04850040 | II | Patients with potentially resectable HCC | Apatinib Mesylate, Camrelizumab and Oxaliplatin | Not yet recruiting |
| Camrelizumab and Apatinib | NCT04701060 | II | Resectable primary HCC patients | Camrelizumab Combined With Apatinib | Recruiting |
| Camrelizumab, Apatinib and chemotherapy | NCT04479527 | II | Advanced HCC patients | (cTACE or DEB-TACE + FOLFOX regimen HAIC) combined with Camrelizumab and Apatinib | Not yet recruiting |
| Apatinib and SHR-1210 | NCT02942329 | I/II | HCC or gastric cancer patients | Apatinib and SHR-1210 | Unknown |
| Camrelizumab and Apatinib | NCT04826406 | II | HCC patients previously treated with immune checkpoint inhibitors | Camrelizumab combined with Apatinib regimen | Recruiting |
| SHR-1210 and Apatinib | NCT03793725 | II | Patients with unresectable HCC | SHR1210 combined with Apatinib | Unknown |
| Apatinib and SHR-1210 | NCT03839550 | II | HCC patients with high risk of recurrence after radical resection | Hepatic Arterial Infusion (HAI) of Apatinib Mesylate + PD-1 antibody SHR-1210. | Not yet recruiting |
| Camrelizumab Plus Apatinib | NCT04639180 | III | Patients with HCC at high risk of recurrence after surgical | Camrelizumab plus Apatinib as adjuvant therapy in HCC | Not yet recruiting |
| M1-c6v1, SHR-1210 and Apatinib | NCT04665362 | I | HCC patients | Recombinant oncolytic virus M1-c6v1, anti-PD-1 antibody SHR-1210, and Apatinib | Not yet recruiting |
| Camrelizumab plus Apatinib | NCT04035876 | I/II | Downstaging/bridging of HCC patients before liver transplant | Camrelizumab (SHR-1210) and Apatinib combination | Recruiting |
| Radiotherapy, and Apatinib | NCT03732105 | II | HCC patients received curative resection with microvascular invasion | Radiotherapy, Apatinib, or radiotherapy + Apatinib | Not yet recruiting |
| TACE, Camrelizumab and Apatinib | NCT04559607 | Not Applicable | Intermediate and advanced HCC patients | TACE combined with Camrelizumab and Apatinib | Recruiting |
| SHR-1210 and Apatinib | NCT03463876 | II | Advanced HCC patients | SHR 1210 + Apatinib | Active, not recruiting |
| Camrelizumab and Apatinib | NCT04523662 | II | Advanced liver cancer patients | Carrelizumab combined with Apatinib Mesylate and radiotherapy | Not yet recruiting |
| Apatinib | NCT02329860 | III | HCC patients after systemic therapy | Apatinib or placebo | Completed |
| Apatinib and TACE | NCT02702323 | II/III | Patients with pulmonary metastasis of liver cancer | Apatinib combined with TACE | Unknown |
| Thermal Ablation, Apatinib and Carilimub | NCT04204577 | II | Advanced liver cancer patients | Thermal ablation combined with Apatinib and Carilimub | Recruiting |
| Apatinib | NCT03261791 | II | HCC patients with PVTT who underwent radical resection | Adjuvant therapy with Apatinib | Unknown |
| SHR-1210 and Apatinib | NCT03764293 | III | Advanced HCC patients | SHR-1210 in Combination With Apatinib as first-line therapy vs. Sorafenib | Recruiting |